Pioneering a Novel Disease-Modifying Therapy for Obstructive Lung Disease
Aspiro Therapeutics, an innovator developing an advanced, disease-modifying therapy that targets obstructive lung diseases, today announced that its CEO, James Lovgren, will present at Seed Showcase™, part of Biotech Showcase 2025. The presentation, “A Novel Therapy to Treat Obstructive Lung Diseases,” will take place on Tuesday, January 14, 2025, at 11:00 AM PST in Franciscan A (Ballroom Level).
Aspiro Therapeutics is advancing a novel therapy for obstructive lung diseases inspired by club cell secretory protein-16 (CC16). This therapy leverages CC16-derived peptidomimetics to address conditions like asthma and chronic obstructive pulmonary disease (COPD). By mimicking CC16’s protective properties, this disease-modifying approach targets underlying disease mechanisms to restore lung function and prevent progression. Aspiro’s advanced molecular design allows for targeted, precise action with exceptional efficacy, offering hope for a healthier future for those affected by these conditions.
“At Aspiro Therapeutics, we are driven by the opportunity to transform the lives of millions of people living with obstructive lung diseases,” said James Lovgren, CEO of Aspiro Therapeutics. “Our novel peptidomimetic therapy is inspired by a natural protein and driven by cutting-edge molecular design, bringing us closer to a disease-modifying solution for conditions like asthma and COPD. We are eager to share our progress and vision with the broader life sciences community.”
Obstructive lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma, affect over 700 million people globally, posing a significant burden on patients, healthcare systems, and economies. COPD alone is the third leading cause of death worldwide and currently has no curative treatment. Existing therapies primarily manage symptoms but fail to address the underlying progression of the disease, leaving millions of patients with limited options and unmet needs. This critical gap underscores the urgent demand for innovative therapies that can provide lasting relief, slow disease progression, and fundamentally improve patient outcomes.
About Aspiro Therapeutics
Aspiro Therapeutics is a preclinical-stage biopharmaceutical company advancing a novel peptidomimetic therapy inspired by club cell secretory protein-16 (CC16). Designed to treat obstructive lung diseases such as asthma and chronic obstructive pulmonary disease (COPD), this innovative therapy mimics CC16’s protective properties to target the underlying mechanisms of these conditions and prevent disease progression. Leveraging advanced molecular design, Aspiro is dedicated to transforming respiratory health and improving patient outcomes. Based in Tucson, AZ, Aspiro is shaping the future of treatments for obstructive lung diseases. For more information, please visit www.aspirotx.com.
Contact:
Kristen White
Kristen@oakstreetcommunications.com